Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 53, Issue 3, 2004, Pages 353-357

  Yanagawa, Tatsuo ^a   Araki, Atsushi ^b   Sasamoto, Kazuo ^b   Shirabe, Shinichiro ^b   Yamanouchi, Toshikazu ^b  

^a Nerima General Hospital   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLICLAZIDE; HEMOGLOBIN A1C; IMMUNOREACTIVE INSULIN; PIOGLITAZONE; TRIACYLGLYCEROL; 1,5 ANHYDROSORBITOL; 1,5-ANHYDROGLUCITOL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; CREATININE; DEOXYGLUCOSE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; ALBUMINURIA; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; URINE;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; BLOOD GLUCOSE; CHOLESTEROL; CREATININE; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 1842506316     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.10.025     Document Type: Article

References (28)

1. Bennett PH, Haffner S, Kasiske BL, et al: Screening and management of microalbuminuria in patients with diabetes mellitus. Am J Kidney Dis 25:107-112, 1995
2. Mimran A, Ribstein J: Microalbuminuria in essential hypertension. J Hum Hypertens 10:657-661, 1996
3. Gosling P: Microalbuminuria and cardiovascular risk: A word of caution. J Hum Hypertens 12:211-213, 1998
4. Ohkubo T, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
5. Lewis EJ, Hunsicker LG, Bain R, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
6. Brenner BM, Cooper ME, de Zeeuw D, et al: The RENAAL study investigators effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
7. Jennings PE, Scott NA, Saniabadi AR, et al: Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment. Metabolism 41:36-39, 1992 (suppl 1)
8. Scott NA, Jennings PE, Brown J, et al: Gliclazide: A general free radical scavenger. Eur J Pharmacol 208:175-177, 1991
9. Fu ZZ, Yan T, Chen YJ, et al: Thromboxane/prostacyclin balance in type II diabetes: Gliclazide effects. Metabolism 41:33-35, 1992 (suppl 1)
10. Akanuma Y, Kosaka K, Kanazawa Y, et al: Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. Diabetes Res Clin Pract 13:81-90, 1998
11. Miyazaki Y, Mahankali A, Matsuda M, et al: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
12. Chilcott J, Tappenden P, Jones ML, et al: A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23:1792-1823discussion p 1791, 2001
13. Yoshimoto T, Naruse M, Nishikawa M, et al: Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 272:E989-996, 1997
14. Kotchen TA, Zhang HY, Reddy S, et al: Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 270:R660-666, 1996
15. Yamanouchi T, Inoue T, Ogata E, et al: Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. Clin Sci (Colch) 101:227-233, 2001
16. Deckert T, Feldt-Rasmussen B, Borch-Johnson K, et al: Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32:219-226, 1989
17. Jensen JS: Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler Thromb Vasc Biol 15:1324-1329, 1995
18. Jensen JS, Borch-Johnsen K, Jensen G, et al: Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Colch) 88:629-633, 1995
19. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabeties. N Engl J Med 310:356-360, 1984
20. Chaiken RL, Khawaja R, Bard M, et al: Utility of untimed urinary albumin measurements in assesing albuminuria in black NIDDM subjects. Diabetes Care 20:709-713, 1997
21. American Diabetes Association: Diabetic nephropathy (Position Statement). Diabetes Care 23:S69-S72, 2000 (suppl 1)
22. Tominaga M, Eguchi H, Manaka H, et al: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
23. Shaw JE, Hodge AM, de Courten M, et al: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42:1050-1054, 1999
24. Wang X, Shaw S, Amiri F, et al: Inhibition of the JAK/STAT signaling pathway prevents the high glucose-induced increase in TGF-and fibronectin synthesis in mesangial cells. Diabetes 51:3505-3509, 2002
25. Doublier S, Salvidio G, Lupia E, et al: Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52:1023-1030, 2003
26. Atchley D, Lopes-Virella M, Zheng D, et al: Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 45:1562-1571, 2002
27. Gram J, Jespersen J: Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Am J Med 24(90):62S-66S, 1991
28. Imano E, Kanda T, Nakatani Y, et al: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21:2135-2139, 1998